rct
    2012

    The efficacy of silymarin in decreasing transaminase activities in non-alcoholic fatty liver disease: a randomized controlled clinical trial

    Hajiaghamohammadi AA, Ziaee A, Oveisi S

    Published in Hepatitis Monthly

    Key Findings

    Silymarin reduced transaminase levels more than metformin or pioglitazone comparators in NAFLD over eight weeks.

    Conclusions

    Supportive but short-term surrogate data.

    Limitations

    Open comparison, short duration.

    Supplements Studied

    Silymarin lowered transaminase levels in NAFLD over eight weeks.

    Related Health Concerns

    Non-Alcoholic Fatty Liver Disease

    Study Details

    Year:2012
    Sample Size:66
    Duration:8 weeks
    Quality Score:5/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.